Back
Compare AU
Compare SYI vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the State Street SPDR MSCI Aus Select High Dividend Yield ETF (SYI) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
SYI | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 269 | 82 |
Median incremental investment | $1,000.00 | $674.92 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,794.42 | $2,268.60 |
Average age group | > 35 | > 35 |
Key Summary
SYI | CURE | |
|---|---|---|
Strategy | SYI.AX was created on 2010-09-28 by SPDR. The fund's investment portfolio concentrates primarily on high dividend yield equity. The ETF currently has 782.67m in AUM and 57 holdings. The State Street SPDR MSCI Australia Select High Dividend Yield ETF seeks to closely track, before fees and expenses, the returns of the MSCI Australia Select High Dividend Yield Index. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 46.59m in AUM and 158 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | CSL Ltd (12.89 %) ANZ Group Holdings Ltd (9.79 %) National Australia Bank Ltd (9.12 %) | Moderna Inc (2.72 %) Exelixis Inc (1.80 %) Amgen Inc (1.79 %) |
Top 3 industries | Financials (64.34 %) Consumer Discretionary (15.19 %) Energy (14.07 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (100.00 %) | United States (96.74 %) Switzerland (1.43 %) United Kingdom of Great Britain and Northern Ireland (1.23 %) |
Management fee | 0.2 % | 0.45 % |
Key Summary
SYI | CURE | |
|---|---|---|
Issuer | SPDR | Global X |
Tracking index | MSCI Australia Select High Dividend Yield Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.2 % | 0.45 % |
Price | $33.56 | $77.29 |
Size | $807.440 million | $50.133 million |
10Y return | 25.08 % | N/A |
Annual distribution yield (5Y) | 8.90 % | 0.03 % |
Market | ASX | ASX |
First listed date | 29/09/2010 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
SYI | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 269 | 82 |
Median incremental investment | $1,000.00 | $674.92 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,794.42 | $2,268.60 |
Average age group | > 35 | > 35 |
Pros and Cons
SYI | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
SYI | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |